Researchers assessing BPC-157 & TB-500 Blend in Australia need more than a product name and a price. Any evaluation should connect the exact material, the amount listed, the supporting laboratory documents and the requirements of the research project.
This guide follows that evaluation from the regulatory status and research background to report verification, ten-vial catalogue specifications and recorded prices. It focuses on BPC-157 & TB-500 Blend, including the details that make its specification different from other products.
Regulatory status first: TB-500 and thymosin beta-4 have been listed in Schedule 4 and Appendix D (clause 5) of the Poisons Standard since 1 June 2016, so possession without the relevant authority is unlawful in Australia. The October 2026 Poisons Standard retains both entries, TB-500 is not an approved medicine in Australia, and “research use” labelling does not change that status. The TB-500 component carries that status in any blend that contains it. This guide is an evidence and documentation reference, not an offer of supply or a statement of availability. The TB-500 and thymosin beta-4 evidence map sets out the regulatory record and the published studies.
Eternal Peptides Wholesale currently lists 5mg BPC-157 + 5mg TB-500 (BB10); 10mg BPC-157 + 10mg TB-500 (BB20). The quantities and prices in this guide reflect the catalogue snapshot of 27 September 2026; they are recorded here as a dated snapshot, not as a statement of current availability. 1 2
By Dr. Sarah Chen, PhD Pharmacology
About the Author
Dr. Sarah Chen, PhD Pharmacology. About Eternal Peptides Wholesale.
What is BPC-157 & TB-500 Blend? Understanding the Research Compound
The catalogue offers BPC-157 and TB-500 together in nominal 5mg/5mg and 10mg/10mg presentations. These are two-component blends, so both the component amounts and the total amount matter when comparing Australian offers. 1 2
The research background comes from separate ingredient studies. BPC-157 has been examined in rat-tendon models; full-length thymosin beta-4 has been examined in wound models. Neither paper tested these finished catalogue blends. 3 4
The scope here is laboratory research. Eternal Peptides Wholesale’s terms restrict products to the stated research audience and exclude human or animal consumption and therapeutic use. A catalogue listing or “research use only” wording is not, by itself, a regulatory exemption; the Therapeutic Goods Administration explains that product classification and applicable obligations still matter. 5 6
Why BPC-157 & TB-500 Blend Attracts Combined Tissue-Model Research Interest
A combination product creates a different experimental question from either ingredient alone. The cited BPC-157 work does not establish a beneficial interaction with TB-500, and the thymosin beta-4 study does not establish the effect of the commercial blend. 3 4
TB-500 identity also needs care: an analytical publication used that name for an acetylated fragment. Confirm which form is present in the blend before using full-length thymosin beta-4 research as its biological rationale. 7
For evaluation, the useful evidence is a declared composition and separate analytical identification and content measurements for each component. A claim of “synergy” would require relevant combination data; it is not inferred here.
Use each reference for the question it actually studied. An analytical paper may support identification; a cellular or animal experiment may support a mechanism; a clinical trial may support findings in its specified population and formulation. None of these replaces a certificate for the lot being considered. The references are a starting set for scientific review, rather than a claim to exhaust the literature.
BPC-157 & TB-500 Blend in Australia: Evaluation Criteria
Start with whether the activity is lawful (see the regulatory status above), then with a listing that identifies exactly what the material is. For BPC-157 & TB-500 Blend, that means a named product, a stated vial quantity, a clear box size and documentation that can be connected to the offered material. The catalogue options are linked above so these details can be checked directly.
Eternal Peptides Wholesale describes itself as a distributor for laboratory research, provides product pages and a testing directory, and offers contact through its published enquiry channels. Those are checkable website features. 8 9 10 Its Shipping Policy also states that dispatch origin can vary and may include offshore fulfilment.
Before relying on a listing, establish four practical points:
- The exact BPC-157 & TB-500 Blend specification required by the laboratory.
- The SKU, nominal amount and number of vials in the offer.
- Which analytical reports relate to the lot that would be supplied.
- How an unresolved specification or documentation question will be answered in writing.
Read 5mg/5mg as 5mg of each named component per vial, giving 10mg total. Read 10mg/10mg as 20mg total. Cost per total milligram is an accounting measure and does not establish the price or activity of either component separately.
Quality Verification: Beyond Marketing Claims
Quality verification should answer the laboratory’s acceptance questions. It should not collapse identity, content, contamination and biological suitability into one marketing percentage.
Pillar 1: Identity, purity and measured content
A percentage and a milligram amount answer different questions. Chromatographic purity is the share of the main peptide peak among the material the HPLC method detects. Net peptide content can also differ from gross material weight because of water, counterions or other constituents. Review identity data and the content method alongside the chromatogram. 11
Pillar 2: Microbial assessment
Kovera Labs sterility testing reports record bacterial and fungal/yeast findings after two days at 30–35°C. View the certificate for the tested sample and batch. 12 13
Pillar 3: Endotoxin measurement
Record the measured result and its unit. A value per vial is different from a value per millilitre, and an appropriate acceptance limit depends on the intended work and method. Sterility testing, reported separately, screens for bacterial and fungal growth. 14
Pillar 4: Heavy-metals screening
The supplied Kovera Labs heavy-metal reports list lead, arsenic, cadmium and mercury, with numerical reporting limits and the certificate’s acceptance criteria. Read the actual analytes and limits for the selected batch. A less-than result is not zero, and the listed panel does not exclude every possible contaminant. 15
| Evidence | What it helps establish | What it does not establish by itself |
|---|---|---|
| Identity and content | The tested identity and measured analyte amount, within method scope | All containers contain the same amount |
| Chromatographic purity | The reported analytical purity under the method | Sterility, total net content or clinical safety |
| Microbial assessment | Observed microbial findings under the stated screening conditions | A different sterility method was performed |
| Endotoxin and metals | Specified analytes and numerical results | Every contaminant has been excluded |
BPC-157 & TB-500 Blend documentation check: Request component-resolved identity and content data. A single overall percentage cannot, by itself, establish both component amounts or the exact TB-500 sequence.
Kovera Labs Testing Explained: What the Reports Actually Show
Eternal Peptides Wholesale links sample reports through product pages and its testing directory. Use these as documents to examine, not as a blanket certification of the catalogue. 9
Find the reports for the selected batch
Use the linked product page and Kovera Labs report directory to find the current displayed documents. Match the product, nominal strength and batch; an old image or a report for a different variant does not establish current-lot coverage.
Our published Kovera Labs reports for this product cover HPLC purity and LC-MS identity, endotoxin, heavy metals and sterility, each with the batch number and report ID. Open the product page to read the results for each batch.
Use the “Verify on Kovera Labs” link for the individual certificate, then compare the laboratory record with the displayed report: sample or report identifier, product, strength, batch, dates, tests and results. Each certificate links to its Kovera Labs verification record, so the report ID and batch can be matched to the supplied stock. Document authentication and matching the report to the material offered are separate checks.
Keep the original documents and a dated record of any verification check. If the report and offered material do not match, contact Eternal Peptides Wholesale for clarification before accepting the lot. A batch number shown on a product photograph is a reference: match it with the written product-page information, the certificate and the actual supplied stock. Each product page shows the batch number with its Kovera Labs reports.
Vial Quantities: Catalogue Specifications and Planning Considerations
The following table summarises the catalogue quantities. It uses nominal labels, not independently measured box contents.
| SKU | Nominal amount per vial | Vials per box | Calculated nominal box amount | Catalogue source |
|---|---|---|---|---|
| BB10 | 5mg BPC-157 + 5mg TB-500 | 10 | 100mg total blend | 1 |
| BB20 | 10mg BPC-157 + 10mg TB-500 | 10 | 200mg total blend | 2 |
For this blend, total milligrams are the sum of nominal component amounts where those amounts are declared. Total blend mass is not the amount of each ingredient. Where the recipe is not published, obtain it before comparing composition with another product.
The catalogue gives a choice of 2 nominal amounts. Compare the actual cost per required amount alongside documentation and stability requirements. A lower cost per mg may be useful for a suitable project, but unused material does not create value.
Document any required storage period and handling conditions before choosing a larger quantity. General peptide-handling guidance cannot validate a shelf life for a specific sequence, solvent or lot; request product-specific stability information where the project needs it. 11
The Wholesale Advantage: Box of 10 Vials
The listed BPC-157 & TB-500 Blend offers use a box of ten vials. This provides a defined unit for budgeting and inventory, with the amounts shown above. 1 2
For a laboratory, the possible value is practical: a known number of containers can be allocated across planned work and recorded against one decision. These are planning considerations, not a claim that a box format improves the compound’s biological performance.
A ten-vial box also does not, by itself, guarantee a single manufacturing lot or uniform measured content. If a project needs all vials from one lot, make that an explicit written requirement and obtain confirmation. Record batch changes rather than treating every future reorder as the same experimental material.
Do not infer a percentage saving against single-vial retail prices without an actual comparable offer. This guide calculates the catalogue’s per-vial equivalent so the arithmetic is visible; it does not invent a market-wide discount.
Business Location: What It Does and Does Not Establish
Any listing can be assessed using the same evidence standard, regardless of where a business is based. Published contact details can make commercial terms easier to evaluate, but location alone does not establish product quality, manufacturing origin or regulatory status.
| Issue | What can be checked for Eternal Peptides Wholesale | What to check with another supplier |
|---|---|---|
| Business description | Published company information 8; the Shipping Policy notes that dispatch may include offshore fulfilment | Actual business identity and operating location |
| Product specification | Linked BPC-157 & TB-500 Blend product listing(s) | Same molecule/form, vial quantity and box size |
| Reports | Product pages and the testing directory 9 | Original records, test scope and current-lot connection |
| Contact | Published enquiry channels 10 | A working route for written specification questions |
| Commercial terms | Published terms and refund policy 5 17 | Written terms applicable to the actual transaction |
The Australian Competition and Consumer Commission explains that Australian Consumer Law can apply to overseas businesses selling directly to Australian consumers, although resolving problems can be harder. Business-to-business rights also depend on the transaction. Avoid simplistic claims that every overseas purchase has no protection or every local purchase is automatically protected in the same way. 18
For BPC-157 & TB-500 Blend, prioritise an answerable specification and a documented lot over general claims about geography. The regulatory classification of the actual product and intended activity must also be checked; a research label alone does not settle it. 6
Red Flags: Warning Signs in Listings and Documentation
Treat the following as reasons to ask for clarification before relying on any BPC-157 & TB-500 Blend listing:
- A product name that does not resolve its precise molecular form or blend composition.
- A report with an unreadable result, missing sample identification or no clear connection to the offered lot.
- A purity percentage being used to imply sterility, clinical safety or guaranteed biological performance.
- Studies of a different compound, formulation or population being presented as proof about the catalogue item.
- A price comparison that mixes vial amounts, box quantities or total blend mass without explaining the basis.
- Refusal to address a material mismatch between the product specification and the supporting documents.
These are procurement checks, not a basis for declaring an unfamiliar business fraudulent. A low price, an overseas address or a missing telephone number alone does not establish misconduct. Make the assessment from the actual evidence and the requirements of the intended work.
Documentation Requirements for Research Institutions
Prepare the documentation file before any material is accepted into a project. A useful record for BPC-157 & TB-500 Blend includes:
- The saved product specification, SKU, nominal amount and agreed box quantity.
- Supplier identity, written records and the terms that apply.
- The batch or lot identifier, report files, test methods and any verification record.
- The laboratory’s acceptance criteria and explanation of how the supplied evidence addresses them.
- Product-specific handling and stability information, with any unresolved gaps recorded.
- Written clarification of differences between the label, the records and a displayed report.
Institutional requirements vary. Ask for a safety data sheet, additional analytical work or other documentation if the institution requires it; this guide does not claim that every such document is publicly available from the supplier. The published contact page provides the route for these enquiries. 10
Keep experimental evidence in a separate part of the file from the product’s quality documents. The scientific references explain the research rationale, while the lot documents explain the material used. This makes it easier for another researcher to understand both decisions later.
Pricing Analysis: Understanding Wholesale Costs
The following prices were displayed in Australian dollars at the 27 September 2026 catalogue snapshot. The per-vial and per-mg figures are calculations from the box price and nominal label amount, rounded to cents. They are not separately advertised sale units or an independent assay of the contents.
| SKU | Listed ten-vial box price | Calculated per-vial equivalent | Calculated cost per nominal mg | Price source |
|---|---|---|---|---|
| BB10 | A$742.50 | A$74.25 | A$7.43 | 1 |
| BB20 | A$1,089.00 | A$108.90 | A$5.45 | 2 |
For this blend, cost per milligram refers to total nominal blend mass, not to each ingredient. These prices are a dated snapshot only.
The catalogue gives a choice of 2 nominal amounts. Compare the actual cost per required amount alongside documentation and stability requirements. A lower cost per mg may be useful for a suitable project, but unused material does not create value.
The lower nominal unit price is only one input. Consider whether the material specification is complete, whether the lot documents meet the institution’s requirements and whether the quantity can be used within supported handling and stability conditions. A price table cannot resolve missing evidence.
Frequently Asked Questions
What is the regulatory status of BPC-157 & TB-500 Blend in Australia?
TB-500 and thymosin beta-4 are listed in Schedule 4 and Appendix D (clause 5) of the Poisons Standard, so possession without the relevant authority is unlawful in Australia. TB-500 is not an approved medicine in Australia, and research-use labelling does not change that status. The TB-500 component carries that status in any blend that contains it. The TB-500 and thymosin beta-4 evidence map sets out the regulatory record.
What makes BPC-157 & TB-500 Blend documentation worth relying on?
A clear product specification, transparent box quantity and price, readable analytical documentation, and a working route for written questions make the documentation easier to evaluate. Assess those points against the actual laboratory requirement rather than relying on a claim that a supplier is “trusted”.
How should a researcher verify the laboratory reports?
Use the laboratory’s own verification route when identifiers are available, then check the sample, batch and method. Authenticate the document and establish the current-lot connection as separate steps. A report image on a product page does not complete both checks. 16
Does research on BPC-157 and thymosin beta-4 prove the blend works better?
No. Separate ingredient studies do not demonstrate the performance, compatibility or interaction of the finished blend. Evaluate the blend composition and analytical data as their own documentation questions. 3 4
Who is the catalogue intended for?
The company’s terms specify the research audience, including qualified researchers or laboratory professionals and age eligibility. They exclude human or animal consumption and therapeutic use. Product classification and applicable requirements still need assessment; a research disclaimer does not create an automatic exemption. 5 6
How should storage and handling be assessed?
Request information specific to BPC-157 & TB-500 Blend, its form and the actual lot. Match the quantity to the laboratory’s validated protocol and supported stability period. General advice about peptides or solvents cannot establish a universal expiry or compatibility rule. 11
Evaluating BPC-157 & TB-500 Blend for Research in Australia
Any evaluation of BPC-157 & TB-500 Blend in Australia starts with the regulatory status of TB-500, then turns on an identified material, a documented quantity and evidence that fits the project. The scientific literature helps explain the research interest; the supplier’s specification and matching reports help evaluate the listed product.
Review the current BPC-157 & TB-500 Blend listing, compare its documents with the published testing directory, and use the contact page to resolve outstanding specification questions. Eternal Peptides Wholesale’s full catalogue provides the other listed research products for comparison.
For the next documentation checks: Read the TB-500 and thymosin beta-4 evidence map; Use the batch-verification checklist; Read the endotoxin reporting-unit guide.
Relevance to Eternal Peptides Wholesale
Eternal Peptides Wholesale publishes this guide alongside its BPC-157 & TB-500 Blend catalogue listings (BPC-157 & TB-500 Blend 10mg + 10mg listing, BPC-157 & TB-500 Blend 5mg + 5mg listing), part of the BPC-157 and TB-500 research catalogue. The aim is to let a laboratory compare a product specification with the published documents before relying on a listing. All listed materials are supplied for laboratory research use only, and a research label is not, by itself, a regulatory exemption.
Batch-specific Kovera Labs reports are collected in the Eternal Peptides Wholesale certificate of analysis library, and our peptide testing standards explain how those reports are used and their limits. The Shipping Policy states that dispatch origin can vary and may include offshore fulfilment, so a listing should not be read as a promise of domestic dispatch.
Further research from Eternal Peptides Wholesale: Peptides wholesale: supplier qualification and quality standards; Synthetic peptides: manufacture, impurities and analytical verification.
References
Catalogue and policy sources checked for this review on 27 September 2026. Research papers are cited for the study described, not as certification of the commercial product.
1. Eternal Peptides Wholesale: BPC-157 & TB-500 (5mg/5mg) Blend – Box of 10 Vials — Catalogue snapshot.
2. Eternal Peptides Wholesale: BPC-157 & TB-500 (10mg/10mg) Blend – Box of 10 Vials — Catalogue snapshot.
3. Staresinic M et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. — Primary research.
4. Malinda KM et al. (1999). Thymosin beta4 accelerates wound healing. — Primary research.
5. Eternal Peptides Wholesale: Terms of service — Company statement; not independent certification.
6. Therapeutic Goods Administration: regulation of therapeutic peptide products — Technical or policy source.
7. Ho EN et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. — Primary research.
8. Eternal Peptides Wholesale: About the company — Company statement; not independent certification.
9. Eternal Peptides Wholesale: Published testing reports — Company statement; not independent certification.
10. Eternal Peptides Wholesale: Contact and enquiries — Company statement; not independent certification.
11. Bachem: peptide quality, net content and handling FAQs — Technical or policy source.
12. Kovera Labs. Sterility testing certificates: results and test conditions. Reports reviewed 1 November 2026; open the individual certificate and its laboratory verification link.
13. United States Pharmacopeia: validation of microbial recovery, chapter 1227 — Technical or policy source.
14. Kovera Labs. Bacterial endotoxin certificates: sample, result, reporting units and limits. Reports reviewed 1 November 2026; open the individual certificate and its laboratory verification link.
15. Kovera Labs. Published Kovera Labs reports and testing scope. Reports reviewed 1 November 2026; open the individual certificate and its laboratory verification link.
16. Kovera Labs. Certificate verification links and sample/batch checks. Reports reviewed 1 November 2026; open the individual certificate and its laboratory verification link.
17. Eternal Peptides Wholesale: Refund policy — Company statement; not independent certification.
18. Australian Competition and Consumer Commission: buying online — Technical or policy source.
Before relying on BPC-157 & TB-500 Blend documentation
Keep the product URL, nominal vial amount, box quantity and batch identifier together in one record. Ask which displayed report corresponds to that lot and which questions remain unanswered. Use the batch-verification checklist when reviewing the documents and the endotoxin results guide when interpreting EU units.
For the regulatory record and the published studies, see the TB-500 and thymosin beta-4 evidence map. Product-specific documentation questions can be sent through the contact page.
Testing references updated 1 November 2026 for the published Kovera Labs report set. Original research and catalogue snapshot dates remain as stated.